Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Anstey A, Lear JT: Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs. 1998 Jan;9(1):33-47.
Marketing Status Prescription; Discontinued
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 72789-129; 51407-182; 46014-1110; 62991-2189; 12780-0300; 51927-2258; 48954-909; 51552-0779; 15308-0732; 42973-143; 68382-120; 38779-0312; 68382-119; 67877-492; 70771-1139; 65649-241; 68382-118; 67877-494; 54766-590; 68462-502; 0378-1005; 71610-124; 60219-2036; 70771-1140; 51927-0071; 65841-602; 68382-003; 71610-306; 42291-071; 60219-2037; 68084-229; 60219-1076; 70771-1141; 49452-0783; 65649-231; 67877-495; 67877-493; 66122-0009
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vitello-intestinal duct remnant03.04.04.007; 07.11.04.0120.001436%Not Available
Fistula discharge08.01.03.069; 15.03.02.0150.003590%Not Available
Gastroenteritis norovirus07.19.03.017; 11.05.22.0010.001436%Not Available
Gastrointestinal viral infection07.19.02.011; 11.05.04.0160.001436%Not Available
Acquired gene mutation08.01.10.0020.001436%Not Available
Inflammatory marker increased13.09.02.0030.004308%Not Available
Mycobacterium tuberculosis complex test positive13.08.05.0040.001436%Not Available
Norovirus test positive13.08.03.0310.001436%Not Available
Epstein-Barr virus associated lymphoma01.15.01.003; 11.05.10.007; 16.28.01.0030.001311%Not Available
Faecal calprotectin increased13.05.02.0050.005744%Not Available
Intestinal fibrosis07.13.01.0130.005026%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000375%Not Available
Anal squamous cell carcinoma07.21.05.004; 16.13.05.0020.000375%Not Available
Small intestine adenocarcinoma07.21.01.015; 16.13.13.0010.000375%Not Available
Abdominal lymphadenopathy01.09.01.020; 07.11.01.0180.002872%Not Available
Large intestinal stenosis07.13.03.0040.021540%
Anorectal swelling07.03.03.0080.001436%Not Available
Phospholipidosis14.08.04.0250.002154%Not Available
Infantile haemangioma16.02.01.007; 24.03.06.0090.001436%Not Available
Gastrointestinal wall thickening07.01.06.0320.004308%Not Available
Kidney congestion02.05.04.017; 20.02.03.0150.000562%Not Available
Non-cirrhotic portal hypertension09.01.06.019; 24.08.06.0030.004308%Not Available
The 27th Page    First    Pre   27    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene